These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 9802339

  • 1. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
    Knecht W, Löffler M.
    Biochem Pharmacol; 1998 Nov 01; 56(9):1259-64. PubMed ID: 9802339
    [Abstract] [Full Text] [Related]

  • 2. Structural and functional comparison of agents interfering with dihydroorotate, succinate and NADH oxidation of rat liver mitochondria.
    Jöckel J, Wendt B, Löffler M.
    Biochem Pharmacol; 1998 Oct 15; 56(8):1053-60. PubMed ID: 9776318
    [Abstract] [Full Text] [Related]

  • 3. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
    Knecht W, Henseling J, Löffler M.
    Chem Biol Interact; 2000 Jan 03; 124(1):61-76. PubMed ID: 10658902
    [Abstract] [Full Text] [Related]

  • 4. Recombinant expression of N-terminal truncated mutants of the membrane bound mouse, rat and human flavoenzyme dihydroorotate dehydrogenase. A versatile tool to rate inhibitor effects?
    Ullrich A, Knecht W, Fries M, Löffler M.
    Eur J Biochem; 2001 Mar 03; 268(6):1861-8. PubMed ID: 11248707
    [Abstract] [Full Text] [Related]

  • 5. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
    Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA.
    Biochemistry; 1996 Jan 30; 35(4):1270-3. PubMed ID: 8573583
    [Abstract] [Full Text] [Related]

  • 6. Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase.
    McLean JE, Neidhardt EA, Grossman TH, Hedstrom L.
    Biochemistry; 2001 Feb 20; 40(7):2194-200. PubMed ID: 11329288
    [Abstract] [Full Text] [Related]

  • 7. Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme.
    Knecht W, Bergjohann U, Gonski S, Kirschbaum B, Löffler M.
    Eur J Biochem; 1996 Aug 15; 240(1):292-301. PubMed ID: 8925840
    [Abstract] [Full Text] [Related]

  • 8. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation.
    Xu X, Williams JW, Gong H, Finnegan A, Chong AS.
    Biochem Pharmacol; 1996 Aug 23; 52(4):527-34. PubMed ID: 8759024
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
    Greene S, Watanabe K, Braatz-Trulson J, Lou L.
    Biochem Pharmacol; 1995 Sep 07; 50(6):861-7. PubMed ID: 7575649
    [Abstract] [Full Text] [Related]

  • 10. Potencies of leflunomide and HR325 as inhibitors of prostaglandin endoperoxide H synthase-1 and -2: comparison with nonsteroidal anti-inflammatory drugs.
    Curnock AP, Robson PA, Yea CM, Moss D, Gadher S, Thomson TA, Westwood R, Ruuth E, Williamson RA.
    J Pharmacol Exp Ther; 1997 Jul 07; 282(1):339-47. PubMed ID: 9223572
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
    Chen SF, Perrella FW, Behrens DL, Papp LM.
    Cancer Res; 1992 Jul 01; 52(13):3521-7. PubMed ID: 1617622
    [Abstract] [Full Text] [Related]

  • 12. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
    Chong AS, Huang W, Liu W, Luo J, Shen J, Xu W, Ma L, Blinder L, Xiao F, Xu X, Clardy C, Foster P, Williams JA.
    Transplantation; 1999 Jul 15; 68(1):100-9. PubMed ID: 10428276
    [Abstract] [Full Text] [Related]

  • 13. In vitro and in Vivo inhibition of immunoglobulin secretion by the immunosuppressive compound HR325 is reversed by exogenous uridine.
    Thomson TA, Spinella-Jaegle S, Francesconi E, Meakin C, Millet S, Flao KL, Hidden H, Ruuth E.
    Scand J Immunol; 2002 Jul 15; 56(1):35-42. PubMed ID: 12100469
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of canine distemper virus replication by blocking pyrimidine nucleotide synthesis with A77 1726, the active metabolite of the anti-inflammatory drug leflunomide.
    Li Y, Yi L, Cheng S, Wang Y, Wang J, Sun J, Zhang Q, Xu X.
    J Gen Virol; 2021 Mar 15; 102(3):. PubMed ID: 33416466
    [Abstract] [Full Text] [Related]

  • 15. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound.
    Williamson RA, Yea CM, Robson PA, Curnock AP, Gadher S, Hambleton AB, Woodward K, Bruneau JM, Hambleton P, Moss D, Thomson TA, Spinella-Jaegle S, Morand P, Courtin O, Sautés C, Westwood R, Hercend T, Kuo EA, Ruuth E.
    J Biol Chem; 1995 Sep 22; 270(38):22467-72. PubMed ID: 7673235
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Expression, purification, and characterization of histidine-tagged rat and human flavoenzyme dihydroorotate dehydrogenase.
    Bader B, Knecht W, Fries M, Löffler M.
    Protein Expr Purif; 1998 Aug 22; 13(3):414-22. PubMed ID: 9693067
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.
    Sawamukai N, Saito K, Yamaoka K, Nakayamada S, Ra C, Tanaka Y.
    J Immunol; 2007 Nov 15; 179(10):6479-84. PubMed ID: 17982036
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.